Biomarkers for treatment with phosphoinositide 3-kinase δ (PI3kδ) inhibitors

WO2026125202A1PCT designated stage Publication Date: 2026-06-18IONCTURA SA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
IONCTURA SA
Filing Date
2025-12-05
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments with PI3K5 inhibitors lack specificity, as they do not effectively identify which patient populations will benefit or not benefit from the therapy, leading to variable treatment outcomes.

⚗Method used

Identification of biomarkers such as olfactory receptors, deubiquitinases, serotonin receptors, GPCR receptors, and immunoregulatory factors to determine individual susceptibility to PI3K5 inhibitor treatment, allowing for personalized treatment strategies.

🎯Benefits of technology

Enables the prediction of treatment responsiveness and selection of appropriate patients for PI3K5 inhibitor therapy, improving treatment efficacy and outcomes by identifying responders and non-responders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000020_0001
    Figure IMGF000020_0001
  • Figure IMGF000021_0001
    Figure IMGF000021_0001
  • Figure 00000035_0000
    Figure 00000035_0000
Patent Text Reader

Abstract

This invention relates to methods of identifying an individual with a disease condition susceptible to treatment with a PI3Kδ inhibitor or determining whether a disease condition in an individual is susceptible to treatment with a PI3Kδ inhibitor. The methods may comprise determining the amount or expression of one or more biomarkers in a sample obtained from the individual. The one or more biomarkers may include olfactory receptors (OR) such as OR10AG1, OR10K1, OR10Q1, OR13C5, OR13C7P, OR1A1, OR1A2, OR1E1, OR1 I1, OR2AP1, OR2B2, OR2B3, OR2H1, OR2J3, OR2K2, OR2M5, OR2T2, OR2Z1, OR4A15, OR4C16, OR4C5, OR4M1, OR4Q3, OR51A7, OR51T1, OR51 V1, OR52K2, OR5AP2, OR5D14, OR5F1, OR5H3P, OR5K4, OR5V1, OR6C4, OR7A10, OR8H3, OR8I2, OR8J1, OR9G4 or OR9Q1; a deubiquitinase (DUB) such as USP17; a serotonin receptor, such as HTR1A, HTR2A or HTR3A; a GPCR receptor such as MTNR1 B, QRFPR, GALR2, GPR37, GPR176, GPR32 or PTGFR; an immunoregulatory factor such as SHIP1; PIK3AP1; CD5; CD5L; PDCD1 or A2M.
Need to check novelty before this filing date? Find Prior Art